PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04655040
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Swedish Ibrance Registries Insights (SIRI)
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1500
- Registration Number
- NCT04654208
- Locations
- 🇸🇪
Pfizer AB, Sollentuna, Sweden
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT04649359
- Locations
- 🇪🇸
Clinica Universitaria de Navarra, Madrid, Spain
🇯🇵Gunma University Hospital, Maebashi, Gunma, Japan
🇺🇸University of Iowa - Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Conditions
- Pediatric Migraine
- Interventions
- Drug: Rimegepant/BHV3000Drug: Matching placebo
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2100
- Registration Number
- NCT04649242
- Locations
- 🇺🇸
Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, Birmingham, Alabama, United States
🇺🇸Perseverance Research Center, LLC, Scottsdale, Arizona, United States
🇺🇸Physicians Research Group, Tempe, Arizona, United States
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
- Conditions
- Tick-Borne Encephalitis
- Interventions
- Biological: TBE vaccine 0.25 mLBiological: TBE vaccine 0.5 mL
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 165
- Registration Number
- NCT04648241
- Locations
- 🇯🇵
Ohigesenseino Kodomo Clinic, Sapporo, Hokkaido, Japan
🇯🇵Medical Co. LTA PS Clinic, Fukuoka,, Fukuoka, Japan
🇯🇵Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Conditions
- ALK-positive NSCLC
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 549
- Registration Number
- NCT04647110
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
- Conditions
- Meningococcal Vaccine
- Interventions
- Biological: MenABCWYBiological: Bivalent rLP2086 (60-µg Dose)Biological: BexseroBiological: Bivalent rLP2086 (120-µg Dose)Drug: Prophylactic Liquid Paracetamol (PLP)Other: PlaceboBiological: NimenrixDrug: Therapeutic Liquid Paracetamol (TLP)Drug: Scheduled Liquid Paracetamol (SLP)
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 326
- Registration Number
- NCT04645966
- Locations
- 🇬🇷
P. & A. Kyriakou Children's Hospital, Athens, Greece
🇩🇪Dr. med Falko Panzer Praxis fuer Kinder und Jugendliche, Mannheim, Germany
🇬🇷University General Hospital "ATTIKON", Athens, Greece
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20vPnC
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 839
- Registration Number
- NCT04642079
- Locations
- 🇺🇸
The Children's Clinic, Jonesboro, Arkansas, United States
🇺🇸Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸Palmetto Pediatrics, PA, North Charleston, South Carolina, United States
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
- Conditions
- Achondroplasia
- Interventions
- Biological: Recifercept
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT04638153
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino - Gemelli IRCCS, Roma, Italy
🇺🇸Nemours Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
🇵🇹Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico, Coimbra, Portugal
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT04635631
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China